Release Date: May 2019
CC: PC, MK, PBL, ICS, PR, SBP
Kristin Hunt Karner, MD
Medical Director of Hematopathology and Molecular Oncology, ARUP Laboratories, Salt Lake City, UT; Assistant Professor, Department of Pathology, University of Utah, Salt Lake City, UT
After completing this course, participants will be able to:
Define clonal hematopoiesis of indeterminate potential, and understand how it differs from an overt myelodysplastic syndrome.
List some of the advantages and disadvantages of using Next Generation Sequencing (massively parallel sequencing) in the evaluation of myeloid malignancies.
Recognize how various myeloid gene mutation patterns relate to the current WHO classification of myeloid malignancies.
Who should attend? Practicing Pathologists, Residents, Doctoral Scientists, Pathologists’ Assistants, Laboratory Managers, Bench Supervisors, Bench Technologists & Technicians
Are you feeling overwhelmed or confused at the increasing complexity of molecular testing in myeloid malignancies? This webcast course will lead you through examples from the initial clinical presentation through the morphologic features of the bone marrow biopsy, and will teach you how to correlate all of this data with the Next Generation Sequencing (NGS) myeloid panel results for an appropriate interpretation. We will discuss the spectrum of myeloid malignancies from Clonal Hematopoiesis of Indeterminate Potential (CHIP) to full-blown Myelodysplastic Syndrome (MDS). We will review the key findings from the literature and break them down into simple, usable strategies that can be incorporated into your daily practice. We will also review both the advantages and the limitations of the myeloid NGS panel. Participants should have some familiarity with basic hematology and bone marrow biopsy interpretation.